• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Galera Therapeutics released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -0.014
04:00
Galera Therapeutics released FY2025 9 Months Earnings on November 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0411
04:00
Aug14
Galera Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.0109
03:00
Galera Therapeutics released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.027
03:00
May16
Galera Therapeutics released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD -0.0161
03:00
Apr1
Galera Therapeutics released FY2024 Q4 earnings on March 31 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.089 USD (forecast -0.3 USD)
03:00

Schedules & Filings

Schedules
Filings
Nov13
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -1.388 M, EPS -0.014

Aug13
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -1.075 M, EPS -0.0109

May15
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -1.592 M, EPS -0.0161

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
HYNE
14.000
+40.00%
+4.000
ASTX
46.070
+36.50%
+12.320
View More